Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

BACKGROUND: This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results from one analytic laboratory. METHODS: Immunogenicity across three trials (EBL2002, EBL2...

Descripción completa

Detalles Bibliográficos
Autores principales: McLean, Chelsea, Barry, Houreratou, Kieh, Mark, Anywaine, Zacchaeus, Tapima Rogers, Baimba, Doumbia, Seydou, Sirima, Sodiomon B., Serry-Bangura, Alimamy, Habib Beavogui, Abdoul, Gaddah, Auguste, Katwere, Michael, Hendriks, Jenny, Keshinro, Babajide, Eholie, Serge, Kibuuka, Hannah, Kennedy, Stephen B., Anzala, Omu, Samai, Mohamed, D'Ortenzio, Eric, Leigh, Bailah, Sow, Samba, Thiébaut, Rodolphe, Greenwood, Brian, Watson-Jones, Deborah, Douoguih, Macaya, Luhn, Kerstin, Robinson, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149382/
https://www.ncbi.nlm.nih.gov/pubmed/37099841
http://dx.doi.org/10.1016/j.ebiom.2023.104562

Ejemplares similares

Ejemplares similares